HC Wainwright Has Positive Outlook for DBVT FY2026 Earnings

DBV Technologies S.A. (NASDAQ:DBVT) – Equities researchers at HC Wainwright boosted their FY2026 earnings estimates for shares of DBV Technologies in a research note issued to investors on Monday, December 15th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($1.85) for the year, up from their previous forecast of ($5.45). HC Wainwright currently has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for DBV Technologies’ current full-year earnings is ($7.05) per share. HC Wainwright also issued estimates for DBV Technologies’ FY2027 earnings at ($1.55) EPS, FY2028 earnings at ($0.30) EPS and FY2029 earnings at $1.80 EPS.

Several other research firms also recently commented on DBVT. Cantor Fitzgerald set a $48.00 price objective on shares of DBV Technologies in a report on Wednesday. Zacks Research upgraded shares of DBV Technologies from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. Guggenheim reiterated a “buy” rating and issued a $51.00 price objective (up from $35.00) on shares of DBV Technologies in a research note on Wednesday. Wall Street Zen raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Friday, November 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of DBV Technologies in a research report on Monday, December 8th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, DBV Technologies has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.

DBV Technologies Stock Performance

NASDAQ DBVT opened at $22.55 on Wednesday. The company has a 50-day simple moving average of $15.11 and a 200 day simple moving average of $11.66. DBV Technologies has a 52-week low of $2.74 and a 52-week high of $26.19. The company has a market capitalization of $905.61 million, a PE ratio of -4.36 and a beta of -1.10.

Hedge Funds Weigh In On DBV Technologies

Several institutional investors have recently modified their holdings of DBVT. New York State Common Retirement Fund purchased a new position in shares of DBV Technologies during the 3rd quarter valued at about $34,000. Two Sigma Investments LP bought a new position in DBV Technologies during the third quarter valued at approximately $167,000. Citadel Advisors LLC purchased a new position in shares of DBV Technologies during the third quarter worth approximately $220,000. DLD Asset Management LP purchased a new position in shares of DBV Technologies during the third quarter worth approximately $250,000. Finally, Nan Fung Trinity HK Ltd. purchased a new stake in shares of DBV Technologies in the 2nd quarter valued at $340,000. 71.74% of the stock is currently owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.